Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 150 от 222

Набира участници

PRIORITY-CONNECT 2 Pilot Trial

Liver Cancer Pancreas Cancer Oesophageal Cancer Gastric Cancer +1

The provision of preoperative interventions (prehabilitation: including exercise, nutrition, and psychological treatment) have been reported to reduce postoperative complications by as much as 50% and reduce hospital stay by up to 4 days compared to standard of care. Postoperative multimodal interventions are likely to further benefit patients facing new challenges (e.g. stoma care), and reduce post discharge complications. Therefore the Virtual Multimodal hub of PRIORITY-CONNECT 2 Pilot Trial aims to primarily; determine the feasibility of incorporating a virtual multimodal program into the preoperative and postoperative period for patients undergoing gastrointestinal cancer surgery, the acceptability to patients, clinicians and carers of the virtual multimodal program and the acceptability to patients of being randomised to the virtual multimodal program or usual care. The secondary aim is to obtain pilot data on the likely difference in key outcomes (30 days postoperative complications, quality of life, days at home and alive at 30 days - DAH30, implementation outcomes and cost outcomes) to inform the development of a substantive randomised clinical trial.

Начало: 12.02.2024 Край: 22.12.2025 Възраст: от 18 г. Поддържаща грижа

Australia Surgical Outcomes Research Centre (SOuRCe) NCT06212700

Набира участници Фаза 1/2

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Advanced Solid Tumors With KRAS G12C Mutations Solid Tumor, Adult Unresectable Solid Tumor Metastatic Solid Tumor +4

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

Начало: 12.02.2024 Край: 01.04.2028 Възраст: от 18 г. Лечение

Australia, South Korea, United States Frontier Medicines Corporation NCT06244771

Набира участници

Cognitive Function and Affective Regulation in Meditators

Cognitive Function and Affective Regulation

This is a prospective cohort study with 52 meditators and 52 controls. These groups will be contacted at a singular timepoint, during which they will take surveys and cognitive tests, which will be used to assess cognitive and emotional outcomes. The meditator group will be recruited from a pool of healthy individuals who have learned meditation practices such as those taught by the Isha Foundation (e.g., Shambhavi Mahamudra Kriya, Shoonya, Samyama breath-watching, etc.) Meditation-naïve individuals will be recruited into the control group.

Начало: 09.02.2024 Край: 31.12.2026 Възраст: от 18 г.

United States Balachundhar Subramaniam NCT07546786

Набира участници Фаза 3

The Role of Peripheral Afferents in Modulating Post-stroke Central Pain

Stroke

Central post-stroke pain (CPP) is extremely difficult to relieve and responds very poorly to analgesics targeting neuropathic pain, probably because the mechanisms underlying this pain remain poorly understood. Stroke pain is traditionally considered to be of central origin and related to changes in the spinal cord and/or brain nociceptive systems. However, a recent study in a small cohort of patients has suggested that the peripheral nervous system (PNS) may have a role in the initiation and persistence of APD. The main objective of this prospective randomised controlled bicentric study (Raymond Poincaré and Ambroise Paré) in double blind and parallel groups against placebo (3 arms) will be to evaluate the efficacy of two peripheral nerve blocks performed 14 days apart on spontaneous neuropathic pain after stroke. The active treatments used for the blocks will be either lidocaine 20 mg/ml or levobupivacaine 1.25 mg/ml or placebo (saline)

Начало: 09.02.2024 Край: 08.09.2026 Възраст: от 18 г.

France Institut National de la Santé Et de la Recherche Médica NCT06446960

Набира участници Фаза 1

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Ovarian Cancer Solid Tumor

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Начало: 09.02.2024 Край: 31.10.2027 Възраст: от 18 г. Лечение

Australia, United States OnCusp Therapeutics, Inc. NCT06234423

Набира участници

Avocado Consumption, Nutrients in Human Milk, and Infant Cognitive Development

Breastfeeding, Exclusive

The goal of this interventional study is to establish a whole food, avocado, as a viable study material to supplement mothers and infants with nutrients that support optimal brain development. Eighty-eight breastfeeding dyads, 3m postnatal, will participate in this study designed to: 1. To document whether lactating mothers will comply in the consumption of 5 avocados a week for 12 weeks. 2. To ascertain the choline, lutein, and fatty acids present in human milk in women who eat avocado. 3. To measure the cognitive advantage conferred to infants whose mothers consume avocados while breastfeeding compared to a non-avocado-eating reference group. To this end, healthy, lactating women who are 13 weeks postpartum and their infants will be enrolled. Mothers will be provided avocados on a bi-weekly basis and will be asked to consume an avocado a day. Infant cognition will be tested when the infants are 4.5 and 6 months of age. Milk samples and diet data will be collected and assayed on a bi-weekly basis.

Начало: 08.02.2024 Край: 31.12.2028 Възраст: 18–40 г.

United States University of North Carolina, Chapel Hill NCT06208085

Набира участници Фаза 3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.

Начало: 08.02.2024 Край: 30.12.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Pfizer NCT06152575

Набира участници Фаза 1/2

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

Glioblastoma Multiforme Astrocytoma, Grade IV

The goal of this clinical trial is to test a combined therapy approach (allogeneic cytomegalovirus \[CMV\]-specific T cells and pembrolizumab) in patients with brain cancer. The type of brain cancer being studied is glioblastoma multiforme/astrocytoma grade 4. The purpose of part 1 of this study is to determine the maximum-tolerated dose and/or recommended dose(s) for future exploration of allogeneic CMV-specific T cells as monotherapy or in combination with pembrolizumab in patients with recurrent GBM/astrocytoma grade 4. Part 2 of the study aims to investigate the anti-tumour activity of allogeneic CMV-specific T cells as monotherapy or in combination with pembrolizumab, assessed by magnetic resonance imaging and survival, in patients with recurrent or newly diagnosed GBM/grade 4 astrocytoma.

Начало: 08.02.2024 Край: 01.01.2028 Възраст: от 18 г. Лечение

Australia Queensland Institute of Medical Research NCT06157541

Набира участници

Essential Fats For Enhancing Cognitive Thinking (EFFECT) Study

Cognitive Decline Cognitive Impairment

The proposed research is a randomized crossover trial designed to assess changes in postprandial cognitive function and the gut-brain axis in adults with subjective cognitive complaints who consume 1 study snack per day for 1 week.

Начало: 07.02.2024 Край: 31.12.2026 Възраст: 40–75 г.

United States Ohio State University NCT06223672

Набира участници

An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App

Hearing Loss

The study is a feasibility, prospective, repeated-measures, multi-country, multi-centre, study of the Mobile Research App to measure and validate speech perception endpoints in adult cochlear implant recipients.

Начало: 05.02.2024 Край: 02.05.2027 Възраст: от 18 г. Фундаментална наука

Australia, Belgium, United States Cochlear NCT06098482

Набира участници Фаза 2

Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer

phase II clinical trial to evaluate node-sparing short-course radiation combined with total neoadjuvant CAPOX and Sintilimab for MSS locally advanced rectal cancers.

Начало: 05.02.2024 Край: 01.09.2028 Възраст: 18–75 г.

China Jinhua Central Hospital NCT06204094

Набира участници Фаза 1/2

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Advanced Head and Neck Squamous Cell Carcinoma Advanced Esophageal Squamous Cell Carcinoma Cervical Squamous Cell Carcinoma +3

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

Начало: 05.02.2024 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, Moldova, Singapore +2 Hummingbird Bioscience NCT05910827

Набира участници Фаза 3

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular Lymphoma (FL)

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world. Participants will receive R2 (intravenous \[IV\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) \[G-CHOP\]/ R-CHOP or G and IV infusion of bendamustine (Benda) \[G-Benda\]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Начало: 05.02.2024 Край: 01.11.2037 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +27 Genmab NCT06191744

Набира участници

Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury

ARDS, Human

Lung protective ventilation with low tidal volumes and low driving pressure are known to reduce mortality in mechanically ventilated patients with acute respiratory failure. This reduction in mortality is known be due to reduction of ventilator induced lung injury that occurs due to high tidal volumes and high driving pressure. When receiving such mechanical ventilation, some patients develop hypercapnia and associated hypercapnic acidosis. Such patients have an increased risk of mortality. While the exact reasons for such increase in mortality is not known, it is recommended to minimise hypercapnia and hypercapnic acidosis during lung protective ventilation. Minimally invasive extracorporeal carbon dioxide removal (ECCO2R) devices are shown to reduce hypercapnia and hypercapnic acidosis. There are several devices that are currently available in the current clinical practice. However, the effect of these devices on reduction in ventilator induced lung injury is not clearly demonstrated. This study aims to assess the use of an ECCO2R device called Prismalung in reducing ventilator induced lung injury. PrismaLung is currently used in our intensive care unit. This assessment is done by measuring interleukins in bronchoalveolar lavage fluid and blood interleukin levels as well as clinical assessment including the reduction of driving pressure.

Начало: 05.02.2024 Край: 28.02.2028 Възраст: от 18 г.

Australia Peninsula Health NCT06321497

Набира участници Фаза 2/3

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial Carcinoma Muscle Invasive Renal Pelvis Urothelial Carcinoma Muscle Invasive Ureter Urothelial Carcinoma Muscle Invasive Urethral Urothelial Carcinoma +3

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.

Начало: 02.02.2024 Край: 02.09.2030 Възраст: от 18 г.

Canada, United States National Cancer Institute (NCI) NCT05987241

Набира участници

INfectious DIsease REgistry BIObank

Bloodstream Infections Central Nervous System Infections Bone and Joint Infections Endovascular Infections +3

Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.

Начало: 01.02.2024 Край: 31.07.2044 Възраст: от 18 г.

Italy IRCCS San Raffaele NCT06418048

Набира участници Фаза 2/3

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Colorectal Cancer Liver Metastases

The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in the liver, increase T lymphocyte infiltration, and consequently improve the postoperative prognosis for patients with surgically resectable colorectal cancer liver metastases (RAS/BRAF wild-type, pMMR/MSS) compared to FOLFOX alone.

Начало: 01.02.2024 Край: 31.12.2029 Възраст: 18–75 г.

China Sun Yat-sen University NCT06280495

Набира участници Фаза 2

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

Cystic Fibrosis

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Начало: 01.02.2024 Край: 31.12.2026 Възраст: 18–60 г. Лечение

France, Netherlands, New Zealand +2 ReCode Therapeutics NCT06237335

Набира участници

PEP-buddy in COPD: Effect on Dyspnea Severity and Mechanism of Action

COPD

Chronic dyspnea is the most characteristic symptom of patients with Chronic Obstructive Pulmonary Disease (COPD), with intermittent increases during exercise and other events.Despite optimal standard therapy, episodic dyspnea is a common occurrence in COPD. Recently, the PEP buddy was developed which is an easy-to use, hands-free device that generates positive expiratory pressure (PEP). Although currently the available evidence is limited, it indicates that utilizing the PEP-buddy can result in enhancements in dyspnea during exertion, exertional desaturation and overall quality of life. More research is needed to evaluate the effectiveness of this device and the long term usability, as well as getting more insight in the mechanism of action. Therefore, the aim of our study is to explore the potential of this device for patients with COPD and episodic breathlessness.

Начало: 31.01.2024 Край: 31.12.2026 Възраст: от 40 г.

Netherlands University Medical Center Groningen NCT05938738

Набира участници

Enriched Holistic Care to Eradicate Disparities in Maternal Morbidity

Morbidity;Perinatal

The goal of this randomized controlled intervention trial is to evaluate an integrated, interdisciplinary, multi-level maternity care home model (MCHM) aimed at reducing severe maternal morbidity (SMM) among a group of Black indigenous and people of color (BIPOC) patients. The main question it aims to answer is whether a patient-centered MCHM will address the gap in social, structural, and health system factors that contribute to disparities for the most vulnerable patients, thereby reducing SMM. Participants will be randomized to a MCHM (office-based prenatal care that is integrated with social services within the MCHM) or standard of care (office-based prenatal care with individually outsourced social services referrals) and followed during pregnancy through 1 year postpartum.

Начало: 30.01.2024 Край: 31.01.2028 Възраст: 16–55 г.

United States University of Pennsylvania NCT06245057

1 … 148 149 150 151 152 … 222